On the other hand, we found no correlation between tumor phospho‐ERK1/2 and SOX9 protein levels, indicating that SOX9 is unlikely to be activated by phospho‐ERK1/2 via the EGFR‐ERK‐SOX9 axis as reported in urothelial cancer (Fig. 3G) [34]. This evidence concerns the gene MAPK3 and neoplasm.